<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Colistin (colistimethate): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Colistin (colistimethate): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Colistin (colistimethate): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8718" href="/d/html/8718.html" rel="external">see "Colistin (colistimethate): Drug information"</a> and <a class="drug drug_patient" data-topicid="10898" href="/d/html/10898.html" rel="external">see "Colistin (colistimethate): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F154558"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Coly-Mycin M</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866437"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Coly-Mycin M</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046591"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span></li></ul></div>
<div class="block don drugH1Div" id="F53462412"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Due to risk of toxicity and efficacy limitations, systemic use is limited to when less toxic alternatives are not effective or not tolerated. When used, typically recommended as part of combination therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31844014','lexi-content-ref-31872226','lexi-content-ref-30710469','lexi-content-ref-34864936','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31844014','lexi-content-ref-31872226','lexi-content-ref-30710469','lexi-content-ref-34864936','lexi-content-ref-35439291'])">Ref</a></span>). Dosage expressed in terms of colistin base activity (CBA). <b>CBA 1 mg</b> is defined to be equivalent to<b> colistimethate sodium (CMS) 30,000 units, which is equivalent to ~2.4 mg CMS</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.1','lexi-content-ref-30710469','lexi-content-ref-16723606','lexi-content-ref-23728146','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.1','lexi-content-ref-30710469','lexi-content-ref-16723606','lexi-content-ref-23728146','lexi-content-ref-28011614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Preterm and term neonates: IM, IV: 2.5 to 5 mg CBA/kg/day divided every 6 to 12 hours; for more severe infections, most commonly reported dose is 5 mg/kg/day divided every 8 hours as part of a combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33108082','lexi-content-ref-32198160','lexi-content-ref-28135233','lexi-content-ref-30073562','lexi-content-ref-28501490','lexi-content-ref-31469781','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33108082','lexi-content-ref-32198160','lexi-content-ref-28135233','lexi-content-ref-30073562','lexi-content-ref-28501490','lexi-content-ref-31469781','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad1a4b51-9af0-4598-86b2-cc608abe0f14">CNS infection, multidrug resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS infection (VP-shunt infection, ventriculitis, meningitis), multidrug resistant:</b> Variable doses reported; optimal dose not defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: Very limited data available: Intraventricular/Intrathecal: 0.16 to 0.24 mg CBA/kg/dose every 24 to 48 hours; usual maximum reported dose: 2 to 4.2 mg CBA/dose; reported duration: 6 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28841583','lexi-content-ref-32198160','lexi-content-ref-33553063','lexi-content-ref-31033908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28841583','lexi-content-ref-32198160','lexi-content-ref-33553063','lexi-content-ref-31033908'])">Ref</a></span>). Doses should be individualized based on culture/susceptibility, minimum inhibitory concentration (MIC), and tolerability, with consideration of patient size and cerebrospinal fluid volume.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c5e8c9d0-5d7c-4644-9094-bf8954c6c36a">Pulmonary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary infection:</b> Limited data available: Preterm and term neonates: Inhalation: 4 mg CBA/kg/<b>dose</b> via nebulizer every 12 hours in combination with systemic antibiotics; use has been described for up to 14 days; however, treatment duration should be individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32198160','lexi-content-ref-32892635','lexi-content-ref-20812247','lexi-content-ref-26065861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32198160','lexi-content-ref-32892635','lexi-content-ref-20812247','lexi-content-ref-26065861'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F154569"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Due to risk of toxicity and efficacy limitations, systemic use is limited to when less toxic alternatives are not effective or not tolerated. When used, typically recommended as part of combination therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31844014','lexi-content-ref-31872226','lexi-content-ref-30710469','lexi-content-ref-34864936','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31844014','lexi-content-ref-31872226','lexi-content-ref-30710469','lexi-content-ref-34864936','lexi-content-ref-35439291'])">Ref</a></span>). Doses should be based on ideal body weight in obese patients; dosage primarily expressed in terms of colistin base activity (CBA). <b>CBA 1 mg</b> is defined to be equivalent to<b> colistimethate sodium (CMS) 30,000 units, which is equivalent to ~2.4 mg CMS</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.1','lexi-content-ref-30710469','lexi-content-ref-16723606','lexi-content-ref-23728146','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.1','lexi-content-ref-30710469','lexi-content-ref-16723606','lexi-content-ref-23728146','lexi-content-ref-28011614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: IM, IV: 2.5 to 5 mg CBA/kg/<b>day</b> divided every 6 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-Manu.1'])">Ref</a></span>). Higher doses may be necessary in some instances; see dosing for specific indications.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad1a4b51-9af0-4598-86b2-cc608abe0f14">CNS infection, multidrug resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS infection (VP-shunt infection, ventriculitis, meningitis), multidrug resistant:</b> Variable doses reported; optimal dose not defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Very limited data available: Intraventricular/Intrathecal: Reported range: 1 to 4.2 mg CBA/dose once daily in combination with systemic antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19460268','lexi-content-ref-34013828','lexi-content-ref-28203777','lexi-content-ref-16916866','lexi-content-ref-20358244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19460268','lexi-content-ref-34013828','lexi-content-ref-28203777','lexi-content-ref-16916866','lexi-content-ref-20358244'])">Ref</a></span>). Doses should be individualized based on culture/susceptibility, minimum inhibitory concentration (MIC), and tolerability, with consideration of patient size and cerebrospinal fluid volume. Case reports in patients 2 months to 4 years of age have described a titration regimen in which 1 mg CBA is administered on day 1, followed by 2 mg CBA once daily for 1 to 2 days, then 4 mg CBA once daily thereafter for a total of 8 to 18 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34955517','lexi-content-ref-19460268','lexi-content-ref-34013828','lexi-content-ref-16916866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34955517','lexi-content-ref-19460268','lexi-content-ref-34013828','lexi-content-ref-16916866'])">Ref</a></span>). In other case reports, patients aged 1 month to 5 years received intrathecal or intraventricular colistin without titration at a dose of 4.2 mg CBA once daily for 5 to 9 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20119725','lexi-content-ref-20358244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20119725','lexi-content-ref-20358244'])">Ref</a></span>). Doses as high as 10 mg CBA (after titration) have been reported to treat multidrug-resistant <i>Acinetobacter baumannii</i> in an infant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19460268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19460268'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Very limited data available: Intraventricular/Intrathecal: 4.2 mg CBA/day (equivalent to 10 mg <b>CMS</b>/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33575996','lexi-content-ref-28203777','lexi-content-ref-34013828','lexi-content-ref-29743769','lexi-content-ref-34497678','lexi-content-ref-17214907']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33575996','lexi-content-ref-28203777','lexi-content-ref-34013828','lexi-content-ref-29743769','lexi-content-ref-34497678','lexi-content-ref-17214907'])">Ref</a></span>). Reported range: 2 to 8.3 mg CBA/day in 1 or 2 divided doses; duration of 10 to 14 days most commonly reported; however, use for up to 24 days has been described; most commonly administered in a single daily dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33575996','lexi-content-ref-24728736','lexi-content-ref-34013828','lexi-content-ref-10825065','lexi-content-ref-23201321']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33575996','lexi-content-ref-24728736','lexi-content-ref-34013828','lexi-content-ref-10825065','lexi-content-ref-23201321'])">Ref</a></span>). In some reports, the dose was titrated up from 2.1 mg CBA once daily to 4.2 mg CBA once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34013828','lexi-content-ref-17214907']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34013828','lexi-content-ref-17214907'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc30ca9c-db9e-4f82-ad38-00cf0b11a720">Cystic fibrosis, pulmonary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, pulmonary infection:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Acute pulmonary exacerbation: Children ≥5 years and Adolescents: IV: Usual reported range: 3 to 5 mg CBA/kg/day divided every 8 hours; maximum dose: 100 mg CBA/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1763528','lexi-content-ref-11402633','lexi-content-ref-22949160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1763528','lexi-content-ref-11402633','lexi-content-ref-22949160'])">Ref</a></span>); doses &gt;5 mg CBA/kg/day (up to 8 mg CBA/kg/day) have been described; however, higher doses are associated with more severe toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1763528','lexi-content-ref-11402633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1763528','lexi-content-ref-11402633'])">Ref</a></span>). Treatment duration varies and is dependent on patient-specific factors, including response to therapy; typical duration is 10 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31487382','lexi-content-ref-34588142','lexi-content-ref-27139161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31487382','lexi-content-ref-34588142','lexi-content-ref-27139161'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Inhaled: Children and Adolescents: Inhalation: Usual dose: 75 to 150 mg CBA via nebulizer every 12 hours; reported range: 33 to 150 mg CBA/dose; administration of doses ≤66 mg has been reported as frequently as every 8 hours. Duration depends on specific use (eg, maintenance therapy vs eradication therapy) and should be individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28614995','lexi-content-ref-12358344','lexi-content-ref-34806975','lexi-content-ref-20500046','lexi-content-ref-22762867','lexi-content-ref-27576543','lexi-content-ref-22379071','lexi-content-ref-20729233','lexi-content-ref-Waters.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28614995','lexi-content-ref-12358344','lexi-content-ref-34806975','lexi-content-ref-20500046','lexi-content-ref-22762867','lexi-content-ref-27576543','lexi-content-ref-22379071','lexi-content-ref-20729233','lexi-content-ref-Waters.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="08e33a60-0755-408b-bb33-2cf5e44040f1">Pulmonary infection due to multidrug-resistant gram-negative bacilli</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary infection due to multidrug-resistant gram-negative bacilli (eg, <i>P. aeruginosa, Acinetobacter</i> spp):</b> Limited data available: <b>Note: </b>Use in combination with systemic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-25939411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-25939411'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Inhalation: 4 mg/kg/dose via nebulizer every 12 hours; maximum dose: 75 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25939411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25939411'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Inhalation: 75 to 150 mg CBA via nebulizer every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20500046','lexi-content-ref-25939411','lexi-content-ref-24673698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20500046','lexi-content-ref-25939411','lexi-content-ref-24673698'])">Ref</a></span>); reported range: 30 to 150 mg CBA/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33713930','lexi-content-ref-20658485','lexi-content-ref-20500046','lexi-content-ref-25939411','lexi-content-ref-24673698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33713930','lexi-content-ref-20658485','lexi-content-ref-20500046','lexi-content-ref-25939411','lexi-content-ref-24673698'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d64f970-a7e6-463a-ac54-a631497c7616">Systemic infections, due to multidrug-resistant gram-negative bacilli</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic infections (eg, bacteremia, pneumonia) due to multidrug-</b>
<b>resistant gram-negative bacilli (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Typically recommended as part of an appropriate combination regimen. Polymyxin B may be preferred over colistin, except for treatment of cystitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31844014','lexi-content-ref-31872226','lexi-content-ref-34864936','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31844014','lexi-content-ref-31872226','lexi-content-ref-34864936','lexi-content-ref-35439291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IM, IV: Loading dose of 2.5 to 5 mg CBA/kg once (maximum dose: 300 mg CBA/dose), followed by 5 mg CBA/kg/day divided every 8 to every 12 hours (maximum dose: 180 mg/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31844014','lexi-content-ref-31872226','lexi-content-ref-24501388','lexi-content-ref-29361414','lexi-content-ref-22935871','lexi-content-ref-32179149']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31844014','lexi-content-ref-31872226','lexi-content-ref-24501388','lexi-content-ref-29361414','lexi-content-ref-22935871','lexi-content-ref-32179149'])">Ref</a></span>). Population pharmacokinetic studies have suggested that higher doses may be necessary to treat severe/critical illness; doses of ~10 mg CBA/kg/day in divided doses have been described; monitor closely for toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33782000','lexi-content-ref-35349496','lexi-content-ref-32773667','lexi-content-ref-30722017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33782000','lexi-content-ref-35349496','lexi-content-ref-32773667','lexi-content-ref-30722017'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity</b>: Infants, Children, and Adolescents: Based on experience with other aminoglycosides, the following should be considered: <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">CNS toxicity: Dose reduction may reduce neurologic symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">Nephrotoxicity: Withhold treatment if signs of renal impairment occur during treatment.</p></div>
<div class="block dorp drugH1Div" id="F51108502"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations in the manufacturer’s labeling; in adult patients, dosage adjustment is suggested.</p></div>
<div class="block dohp drugH1Div" id="F51090201"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F154561"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8718" href="/d/html/8718.html" rel="external">see "Colistin (colistimethate): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Reserve for extensively drug-resistant gram-negative infections (eg, carbapenem-resistant <i>Enterobacterales</i> or <i>A. baumannii</i>, difficult to treat <i>P. aeruginosa</i>) when other agents cannot be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469'])">Ref</a></span>). Dosage expressed in terms of <b>mg</b> of <b>colistin base activity (CBA). CBA 1 mg </b>is defined to be equivalent to <b>colistimethate sodium (CMS) 30,000 units</b> which is equivalent to <b>~2.4 mg CMS</b> (see table below) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.1','lexi-content-ref-30710469','lexi-content-ref-16723606','lexi-content-ref-23728146','lexi-content-ref-24107410','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.1','lexi-content-ref-30710469','lexi-content-ref-16723606','lexi-content-ref-23728146','lexi-content-ref-24107410','lexi-content-ref-28011614'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Colistimethate Sodium Conversion (EMA 2014)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Colistimethate Sodium</p></td>
<td align="center">
<p style="text-indent:0em;">Colistimethate Sodium</p></td>
<td align="center">
<p style="text-indent:0em;">Colistin-Base Activity</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">12,500 units</p></td>
<td align="center">
<p style="text-indent:0em;">1 mg</p></td>
<td align="center">
<p style="text-indent:0em;">0.4 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">150,000 units</p></td>
<td align="center">
<p style="text-indent:0em;">12 mg</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1,000,000 units</p></td>
<td align="center">
<p style="text-indent:0em;">80 mg</p></td>
<td align="center">
<p style="text-indent:0em;">34 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4,500,000 units</p></td>
<td align="center">
<p style="text-indent:0em;">360 mg</p></td>
<td align="center">
<p style="text-indent:0em;">150 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">9,000,000 units</p></td>
<td align="center">
<p style="text-indent:0em;">720 mg</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg</p></td></tr></tbody></table>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When polymyxin use is warranted, polymyxin B is preferred over colistimethate due to significant interpatient variability in pharmacokinetics, slower attainment of desired plasma concentrations, and increased risk of nephrotoxicity with colistimethate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-35439291'])">Ref</a></span>). To minimize development of resistance, use in combination with other antibiotics, depending on infection site and susceptibilities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>300 mg colistin base activity (CBA) loading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570'])">Ref</a></span>). Usual duration is 7 to 14 days depending on source, extent of infection, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34738022','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34738022','lexi-content-ref-30535100'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52c697f3-429c-4126-a68e-17db9149a21e">Bronchiectasis, exacerbation prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchiectasis, exacerbation prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with multidrug-resistant gram-negative pathogens in the sputum and either &gt;3 exacerbations per year or severe exacerbations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barker.1','lexi-content-ref-28889110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barker.1','lexi-content-ref-28889110'])">Ref</a></span>). Dose not well defined and varies widely across studies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Inhalation for nebulization (off-label route):</b> 30 to 150 mg colistin base activity (CBA) via nebulizer once or twice daily (maximum dose: 150 mg CBA twice daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28889110','lexi-content-ref-24625200','lexi-content-ref-20500046','lexi-content-ref-19436571','lexi-content-ref-17547727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28889110','lexi-content-ref-24625200','lexi-content-ref-20500046','lexi-content-ref-19436571','lexi-content-ref-17547727'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df85d498-37b3-4d24-95e1-d4a9ea8cb8c0">Cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute pulmonary exacerbation:</i>
<b> Note:</b> To minimize development of resistance, use in combination with other antibiotics depending on susceptibilities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2.5 to 5 mg/kg/day colistin base activity (CBA) in 3 divided doses. Maximum dose not well defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35678460','lexi-content-ref-UKCF.1','lexi-content-ref-22949160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35678460','lexi-content-ref-UKCF.1','lexi-content-ref-22949160'])">Ref</a></span>); some experts suggest a maximum of 300 mg CBA/day in patients with cystic fibrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Simon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Simon.1'])">Ref</a></span>). Treatment duration is 10 to 14 days depending on patient-specific factors, including initial response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34469706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34469706'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic P. aeruginosa pulmonary infection: </i>
<b>Inhalation for nebulization (off-label route):</b> 75 to 150 mg CBA via nebulizer twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20500046','lexi-content-ref-Simon.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20500046','lexi-content-ref-Simon.2'])">Ref</a></span>). Administer in repeated cycles of 28 days on drug followed by 28 days off drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32115388','lexi-content-ref-23540878','lexi-content-ref-Simon.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32115388','lexi-content-ref-23540878','lexi-content-ref-Simon.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When polymyxin use is warranted, polymyxin B is preferred over colistimethate due to significant interpatient variability in pharmacokinetics, slower attainment of desired plasma concentrations, and increased risk of nephrotoxicity with colistimethate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-35439291'])">Ref</a></span>). To minimize development of resistance, use in combination with other antibiotics, depending on infection site and susceptibilities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>300 mg colistin base activity (CBA) loading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570'])">Ref</a></span>). Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When systemic polymyxin use is warranted, polymyxin B is preferred over colistimethate due to significant interpatient variability in pharmacokinetics, slower attainment of desired plasma concentrations, and increased risk of nephrotoxicity with colistimethate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-35439291'])">Ref</a></span>). To minimize development of resistance, use in combination with other antibiotics, depending on infection site and susceptibilities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655'])">Ref</a></span>). Intraventricular/intrathecal administration is generally reserved for meningitis or ventriculitis that is refractory to appropriate parenteral therapy or associated with intraventricular devices that cannot be removed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 300 mg colistin base activity (CBA) loading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570'])">Ref</a></span>). Treatment duration is ≥10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>); some experts recommend ≥21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intrathecal/intraventricular (adjunctive agent) (off-label route) (use a preservative-free preparation):</b> 4.2 mg CBA per day in 1 or 2 divided doses; administer in combination with appropriate systemic antimicrobial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-28203777','lexi-content-ref-22687507','lexi-content-ref-23335739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-28203777','lexi-content-ref-22687507','lexi-content-ref-23335739'])">Ref</a></span>). <b>Note:</b> When intraventricular colistimethate is administered via a ventricular drain, clamp drain for 15 to 60 minutes after administration (allows solution to equilibrate in cerebrospinal fluid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When systemic polymyxin use is warranted, polymyxin B is preferred over colistimethate due to significant interpatient variability in pharmacokinetics, slower attainment of desired plasma concentrations, and increased risk of nephrotoxicity with colistimethate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-35439291'])">Ref</a></span>). To minimize development of resistance, use in combination with other antibiotics, depending on infection site and susceptibilities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655'])">Ref</a></span>). Some experts prefer to add inhaled colistimethate for patients with serious hospital-acquired or ventilator-associated pneumonia that requires treatment with IV colistimethate due to low lung concentrations with IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanafani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanafani.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 300 mg colistin base activity (CBA) loading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570'])">Ref</a></span>). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Inhalation for nebulization (adjunctive agent) (off-label route):</b> Dose not well defined: 75 to 150 mg CBA twice daily in combination with systemic antimicrobial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24274315','lexi-content-ref-30710469','lexi-content-ref-27418577','lexi-content-ref-20876621','lexi-content-ref-25493971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24274315','lexi-content-ref-30710469','lexi-content-ref-27418577','lexi-content-ref-20876621','lexi-content-ref-25493971'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a74533c8-554a-440e-8601-6b5e9cffeae7">Sepsis and septic shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sepsis and septic shock:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When polymyxin use is warranted, polymyxin B is preferred over colistimethate due to significant interpatient variability in pharmacokinetics, slower attainment of desired plasma concentrations, and increased risk of nephrotoxicity with colistimethate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-35439291'])">Ref</a></span>). To minimize development of resistance, use in combination with other antibiotics, depending on infection site and susceptibilities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>300 mg colistin base activity (CBA) loading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570'])">Ref</a></span>); use in combination with other appropriate agents. Initiate therapy as soon as possible and preferably within 1 hour of recognition of sepsis or septic shock. Duration is dependent on underlying source and patient response; short courses are preferred, when appropriate. Discontinue if a noninfectious etiology is identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Colistimethate is the preferred polymyxin for urinary tract infections because of higher urinary concentrations compared to polymyxin B (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-34864936','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-34864936','lexi-content-ref-35439291'])">Ref</a></span>). To minimize development of resistance, may use in combination with other antibiotics, depending on susceptibilities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25630411','lexi-content-ref-30710469','lexi-content-ref-25461655'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 300 mg colistin base activity (CBA) loading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi-content-ref-19433570'])">Ref</a></span>). Total duration of therapy ranges from 5 to 14 days; for patients with symptomatic improvement within the first 48 to 72 hours of therapy, some experts recommend shorter courses of 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1','lexi-content-ref-21292654','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1','lexi-content-ref-21292654','lexi-content-ref-30535100'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991865"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Dosage expressed in terms of <b>colistin base activity (CBA);</b> although reported conversions have varied slightly in the literature,<b> CBA 1 mg </b>is defined to be equivalent to<b> colistimethate sodium 30,000 units</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.1','lexi-content-ref-16723606','lexi-content-ref-23728146','lexi-content-ref-24107410','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.1','lexi-content-ref-16723606','lexi-content-ref-23728146','lexi-content-ref-24107410','lexi-content-ref-28011614'])">Ref</a></span>). These dosing recommendations should achieve a target average colistin steady-state plasma concentration of 2 mg/L and are derived from analysis of pharmacokinetic data in critically ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28011614'])">Ref</a></span>). For inhaled, intrathecal, and intraventricular colistin, there are no specific dosage adjustments recommended (has not been studied); however, need for adjustment unlikely due to low systemic absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: <b>IV:</b> 300 mg CBA, followed by a maintenance dose based on CrCl (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-28011614'])">Ref</a></span>) calculated using the Cockcroft-Gault equation with an adjusted body weight (ideal body weight [IBW] + 0.4 [total body weight – IBW]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-28011614','lexi-content-ref-22576791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-28011614','lexi-content-ref-22576791'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: <b>IV:</b> The following total daily maintenance doses (administered in 2 divided doses) are recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-28011614'])">Ref</a></span>); begin maintenance dose 12 hours after the loading dose:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥90 mL/minute: 360 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 80 to &lt;90 mL/minute: 340 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 70 to &lt;80 mL/minute: 300 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 60 to &lt;70 mL/minute: 275 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to &lt;60 mL/minute: 245 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 to &lt;50 mL/minute: 220 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to &lt;40 mL/minute: 195 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 to &lt;30 mL/minute: 175 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to &lt;20 mL/minute: 160 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 5 to &lt;10 mL/minute: 145 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;5 mL/minute: 130 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Alternative renal dosing strategy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.1','lexi-content-ref-26607424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.1','lexi-content-ref-26607424'])">Ref</a></span>):</i></b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">For critically ill patients, a loading dose of 300 mg CBA should be administered followed by a maintenance dose based on CrCl. The following total daily maintenance doses (administered in 2 or 3 divided doses) are recommended; begin maintenance dose 12 hours after the loading dose:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: 300 mg CBA/day; patients with good kidney function (CrCl ≥80 mL/minute) may require higher doses &gt;300 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to &lt;50 mL/minute: 183 to 250 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to &lt;30 mL/minute: 150 to 183 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: 117 mg CBA/day.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 360 mg CBA/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> No definitive studies have evaluated colistin pharmacokinetics in ARC. Patients with ARC receiving conventional doses required longer treatments than those without ARC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30709064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30709064'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~30%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25698772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25698772'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: <b>IV:</b> 300 mg CBA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-28011614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Dialysis days: 180 mg CBA on dialysis days (administer after dialysis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-28011614','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-28011614','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Nondialysis days: 130 mg CBA on nondialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-28011614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>IV:</b> Loading dose: 300 mg CBA followed by 150 to 200 mg CBA once daily as maintenance starting 24 hours after the loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24189256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24189256'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour), and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> IV:</b> Loading dose: 300 mg CBA followed by 220 mg CBA every 12 hours as maintenance starting 12 hours after the loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469'])">Ref</a></span>). <b>Note:</b> The pro-drug CMS is removed by CRRT (~10% per hour), therefore patients receiving CRRT require higher daily doses than patients with normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-27474468','lexi-content-ref-23147733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-27474468','lexi-content-ref-23147733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Loading dose: 300 mg CBA followed by maintenance dose based on kidney function and duration of PIRRT session. Add 10% per 1 hour of PIRRT replacement to the recommended baseline daily dose for kidney function (eg, CrCl &lt;5 mL/minute, 130 mg CBA/day); administer in 2 divided doses 12 hours apart starting 12 hours after the loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-28011614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">For example, in a patient with a CrCl of &lt;5 mL/minute receiving 10 hours nocturnal PIRRT session each day, the suggested CBA maintenance dose is: 130 mg + (10 hours × 13) = 260 mg CBA/day, administered as 130 mg every 12 hours. PIRRT session should begin 1 to 2 hours after the afternoon/evening dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469','lexi-content-ref-28011614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469','lexi-content-ref-28011614'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989164"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F154539"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nephrotoxicity (18% to 26% [Dalfino 2012; Oliveira 2009])</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute renal failure (33% to 60% [Akajagbor 2013; Deryke 2010])</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Neurotoxicity (7%; higher incidence with high-dose IV use in cystic fibrosis [Bosso 1991; Koch-Weser 1970])</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness, oral paresthesia, paresthesia, peripheral paresthesia, seizures, slurred speech, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea, gastric distress</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Decreased urine output</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance, increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, respiratory distress</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F154549"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to colistimethate, colistin, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F154536"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchoconstriction: Use of inhaled colistimethate (off-label route) may result in bronchoconstriction. Use with caution in patients with hyperactive airways; consider administration of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (Le 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS toxicity: Transient, reversible neurological disturbances (eg, dizziness, numbness, paresthesia, generalized pruritus, slurred speech, tingling, vertigo) may occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction may reduce neurologic symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Dose-dependent nephrotoxicity has been reported, generally reversible upon discontinuation of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory arrest: Respiratory arrest has been reported with use; impaired renal function may increase the risk for neuromuscular blockade and apnea.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with preexisting renal impairment; dosage adjustments are recommended. Impaired renal function may increase the risk for respiratory arrest.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Inhalation (off-label route): Once mixed, colistimethate begins conversion to bioactive colistin, a component of which may result in severe pulmonary toxicity (Le 2010). Solutions for inhalation must be mixed immediately prior to administration and used within 24 hours to reduce the incidence of pulmonary toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Safety: Potential for dosing errors due to lack of standardization in literature when referring to product and dose. Colistimethate (inactive prodrug) and colistin base strengths are not interchangeable; verify prescribed dose is expressed in terms of colistin base activity prior to dispensing.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878398"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Electrolyte disturbances, including hypomagnesemia, hypokalemia, hypocalcemia, and hyponatremia, have been described in neonates receiving IV colistimethate and may require supplementation. Disturbances have been reported mostly in populations mainly comprised of preterm patients, and risk may be higher in the very low-birth-weight population (weighing &lt;1,500 g at birth); monitor electrolytes closely during therapy (Aksoy 2020; Alan 2014; Ambreen 2020; Antachopoulos 2017; Ilhan 2018; İpek 2017). Electrolyte disturbances may be mediated by renal tubulopathy and associated with other manifestations of kidney toxicity (Thomas 2019; Yurttutan 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Neurotoxicity, which may occur in all ages, may present differently in the neonatal population compared to older pediatric patients; in term or preterm neonates, neurotoxicity may present as apnea or seizures; monitor closely (Alan 2014; Ambreen 2020; Çağan 2017; Nakwan 2019).</p></div>
<div class="block foc drugH1Div" id="F154544"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coly-Mycin M: 150 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F154532"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323078"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Colistimethate Sodium (CBA) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $12.42 - $35.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Coly-Mycin M Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $33.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866438"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coly-Mycin M: 150 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52612455"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer deep into a large muscle mass (eg, gluteal muscle or lateral part of the thigh).</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Administer over 3 to 5 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Administer over 20 to 60 minutes; most commonly infused over 30 minutes in neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33782000','lexi-content-ref-35349496','lexi-content-ref-32892635','lexi-content-ref-30073562','lexi-content-ref-23689704','lexi-content-ref-27276179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33782000','lexi-content-ref-35349496','lexi-content-ref-32892635','lexi-content-ref-30073562','lexi-content-ref-23689704','lexi-content-ref-27276179'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Inhalation: Administer solution via nebulizer promptly following preparation of solution to decrease possibility of high concentrations of colistin from forming, which may lead to potentially life-threatening lung toxicity. Consider use of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20500046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20500046'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> A case report of fatal lung toxicity implicated in vitro colistin formation from an inhalation solution as a potential etiology, but data regarding the concentration, formulation, and storage of the inhaled colistin administered to the patient were not reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-18046039','lexi-content-ref-18606838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-18046039','lexi-content-ref-18606838'])">Ref</a></span>). An acceptable limit of in vitro colistin formation to prevent potential toxicity is unknown. Limited stability data are available regarding the storage of colistin solution for inhaled administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23070159','lexi-content-ref-18606838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23070159','lexi-content-ref-18606838'])">Ref</a></span>). Storing for &gt;24 hours may increase the risk for potential lung toxicity; preparation immediately prior to administration is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-20500046','lexi-content-ref-18606838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-20500046','lexi-content-ref-18606838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Intraventricular/Intrathecal: Administer only preservative-free solutions via intrathecal/intraventricular routes. Administer promptly after preparation. Discard unused portion of vial. When administering via a ventricular drain, clamp the drain for 15 to 60 minutes to allow equilibration of colistin with cerebrospinal fluid prior to opening the drain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28841583','lexi-content-ref-19892577','lexi-content-ref-19460268','lexi-content-ref-34013828','lexi-content-ref-28203777','lexi-content-ref-16916866','lexi-content-ref-34497678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28841583','lexi-content-ref-19892577','lexi-content-ref-19460268','lexi-content-ref-34013828','lexi-content-ref-28203777','lexi-content-ref-16916866','lexi-content-ref-34497678'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F154546"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 30 minutes to 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30710469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30710469'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Inhalation (off-label route): Administer solution via nebulizer (vibrating plate nebulizer may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23132092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23132092'])">Ref</a></span>)) promptly following preparation to decrease possibility of high concentrations of colistin from forming which may lead to potentially life-threatening lung toxicity. Consider use of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20500046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20500046'])">Ref</a></span>). If patient is on a ventilator, place medicine in a T-piece at the midinspiratory circuit of the ventilator. One study in adult patients with VAP administered colistimethate over 60 minutes using a vibrating plate nebulizer positioned on the inspiratory limb 10 cm proximal to the Y-piece (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23132092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23132092'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> A case report of fatal lung toxicity implicated <i>in vitro</i> colistin formation from an inhalation solution as a potential etiology, but data regarding the concentration, formulation and storage of the inhaled colistin administered to the patient were not reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-18046039','lexi-content-ref-18606838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-18046039','lexi-content-ref-18606838'])">Ref</a></span>). An acceptable limit of in vitro colistin formation to prevent potential toxicity is unknown. Limited stability data are available regarding the storage of colistin solution for inhaled administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23070159','lexi-content-ref-18606838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23070159','lexi-content-ref-18606838'])">Ref</a></span>). Storing for &gt;24 hours may increase the risk for potential lung toxicity; preparation immediately prior to administration is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-20500046','lexi-content-ref-18606838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-20500046','lexi-content-ref-18606838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal/intraventricular (off-label route): Administer only preservative-free solutions via intrathecal/intraventricular routes. Administer promptly after preparation. Discard unused portion of vial. When administered through a ventricular drain, clamp drain for 15 to 60 minutes before opening the drain to allow colistimethate solution to equilibrate in the CSF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F154555"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials (prior to reconstitution) at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Reconstituted vials may be refrigerated at 2°C to 8°C (36°F to 46°F) or stored at 20°C to 25°C (68°F to 77°F) for up to 7 days. Solutions for infusion should be freshly prepared in D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, D5NS, D5W, LR, or NS; do not use beyond 24 hours.</p></div>
<div class="block usep drugH1Div" id="F53566243"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute or chronic infections due to certain gram-negative bacilli (particularly <i>Pseudomonas aeruginosa</i>) (FDA approved in all ages); has also been used as inhalation therapy in cystic fibrosis and to treat multidrug-resistant gram-negative pneumonia and as intrathecal/intraventricular therapy to treat multidrug-resistant gram-negative meningitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Due to risk of toxicity and efficacy limitations,<b></b>use has been replaced by alternative agents (Aguilera-Alonso 2020; Chiotos 2020; ESCMID/EUCAST [Tsuji 2019]; IDSA [Tamma 2022a]; IDSA [Tamma 2022b]).</p></div>
<div class="block mst drugH1Div" id="F14219656"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Due to the potential for dosing errors, it is recommended that prescriptions for colistimethate be expressed as mg of colistin base activity only.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299084"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F154540"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Management: Avoid coadministration of colistimethate and aminoglycosides whenever possible due to the risk of nephrotoxicity and neuromuscular blockade. If coadministration cannot be avoided, monitor renal and neuromuscular function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: May enhance the nephrotoxic effect of Colistimethate. Management: Avoid coadministration of colistimethate and amphotericin B whenever possible due to the potential for additive or synergistic nephrotoxicity. If coadministration cannot be avoided, closely monitor renal function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacitracin (Systemic): Colistimethate may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capreomycin: May enhance the neuromuscular-blocking effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefaloridine [Cephaloridine]: Colistimethate may enhance the nephrotoxic effect of Cefaloridine [Cephaloridine]. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefazedone: May enhance the nephrotoxic effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: May enhance the nephrotoxic effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Colistimethate may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Colistimethate may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netilmicin (Ophthalmic): Colistimethate may enhance the nephrotoxic effect of Netilmicin (Ophthalmic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.  Management: If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and colistimethate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymyxin B: Colistimethate may enhance the nephrotoxic effect of Polymyxin B. Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate. Colistimethate may enhance the neurotoxic effect of Polymyxin B.  Management: Coadministration of polymyxin B and other potentially neurotoxic or nephrotoxic agents, such as colistimethate, is generally not recommended. If this combination must be used, monitor carefully for enhanced neurotoxic and nephrotoxic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May enhance the nephrotoxic effect of Colistimethate. Management: Avoid coadministration of colistimethate and vancomycin whenever possible due to the potential for additive or synergistic nephrotoxicity. If coadministration cannot be avoided, closely monitor renal function.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F5105300"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies. Colistimethate crosses the placenta in humans.</p></div>
<div class="block mopp drugH1Div" id="F53566242"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Systemic: SCr, BUN, urine output; sodium, potassium, magnesium, and calcium (in neonates), (Ambreen 2020; Thomas 2019) signs of neurotoxicity; number and type of stools/day for diarrhea.</p>
<p style="text-indent:-2em;margin-left:2em;">Inhalation therapy: Signs of bronchospasm.</p></div>
<div class="block rerp drugH1Div" id="F57301338"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Colistin serum concentrations are recommended when available (Downes 2021; ESCMID/EUCAST [Tsuji 2019]; Ooi 2019; Wacharachaisurapol 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Ensure that sample handling and storage are appropriate to prevent in vitro conversion of colistimethate sodium to colistin; target listed is for colistin concentration (versus total concentrations including derivatives) and approximates an AUC<sub>24</sub> of ~50 mg•hour/L (Downes 2021; ESCMID/EUCAST [Tsuji 2019]; Ooi 2019; Wacharachaisurapol 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">C<sub>ss,avg</sub> (average steady-state concentration): ~2 mg/L.</p></div>
<div class="block pha drugH1Div" id="F154535"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Colistimethate (or the sodium salt [colistimethate sodium]) is the inactive prodrug that is hydrolyzed to colistin, which acts as a cationic detergent and damages the bacterial cytoplasmic membrane causing leaking of intracellular substances and cell death.</p></div>
<div class="block phk drugH1Div" id="F154548"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Not absorbed from the GI tract, mucous membranes, or intact skin (<b>Note:</b> GI absorption has been observed in infants).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">CSF penetration:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents ≤14 years: Colistin: 3% to 19%; may be increased in the presence of meningitis (Antachopoulos 2010).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Colistin: ~5% (Markantonis 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: Colistin: 7.7 ± 9.3 L/kg (Nakwan 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents &lt;15 years: IV: Colistin: 0.6 ± 0.3 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Healthy volunteer:</i> IV: Colistimethate: 8.92 L; Colistin: 12.4 L (Couet 2012).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Critically ill:</i> IV: Colistimethate: 5.3 to 13.5 L; Colistin: 7.2 to 189 L (Couet 2012).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cystic fibrosis:</i> IV: Colistimethate: 10.8 to 31.3 L (Li 2003).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Colistimethate sodium (inactive prodrug) is hydrolyzed to colistin (active form). <b>Note:</b> Only ~30% of colistimethate sodium is converted to colistin (Couet 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IM, IV: All ages: Colistimethate: 2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: Colistin: 9 ± 6.5 hours (Nakwan 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents &lt;15 years (critically ill): IV: Colistin: 2.6 ± 0.4 hours (Wacharachaisurapol 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Critically ill:</i> IV: Colistimethate: 2.3 hours; Colistin: 14.4 hours (Plachouras 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cystic fibrosis:</i> IV: Colistin: ~4 hours (Li 2003).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>End-stage renal disease patients receiving CAPD:</i> IV: Colistin: 13.2 hours (Koomanachai 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: Colistin: 1.3 ± 0.9 hours from end of 0.5-hour infusion (Nakwan 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents &lt;15 years: IV: Colistin: 1.1 ± 0.3 hours from end of 5-minute injection (Wacharachaisurapol 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Healthy volunteers:</i> IV: Colistin: 2 hours (range: 1 to 4 hours) (Couet 2011).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Critically ill:</i> IV: Colistin: ~7 hours (Plachouras 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (as unchanged drug); most colistin recovered in the urine is from postexcretion hydrolysis of colistimethate sodium (Couet 2011).</p></div>
<div class="block phksp drugH1Div" id="F58825283"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Concentration dependent; associated with area under the curve (AUC<sub>24</sub>)/minimum inhibitory concentration (MIC), goal: AUC<sub>24</sub> at steady state ~50 mg•hour/L or an average plasma colistin concentration at steady state (C<sub>ss,avg</sub>) of 2 mg/L (Abdul-Aziz 2020; ESCMID/EUCAST [Tsuji 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>P. aeruginosa</i>: Goal: <i>f</i>AUC<sub>0-24</sub>/MIC: 6.6 to 13.7 (Abdul-Aziz 2020; Cheah 2015).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>A. baumannii</i>: Goal: <i>f</i>AUC<sub>0-24</sub>/MIC: 3.5 to 17.6 (Abdul-Aziz 2020; Cheah 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug concentrations in patients with normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reported concentrations are reflective of active colistin component unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>C<sub>max </sub>(peak):</b></p>
<p style="text-indent:-2em;margin-left:8em;">Neonates (GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: 5 mg colistin base activity (CBA)/kg, single dose: 3 ± 0.7 mg/L (Nakwan 2016).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years of age and adolescents ≤15 years of age: IV:</p>
<p style="text-indent:-2em;margin-left:10em;">1.7 to 2.5 mg CBA/kg, single dose: 4.1 ± 1.3 mg/L (Wacharachaisurapol 2020).</p>
<p style="text-indent:-2em;margin-left:10em;">4 mg CBA/kg, single dose: 6.1 ± 2.4 mg/L (Wacharachaisurapol 2020).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults:</p>
<p style="text-indent:-2em;margin-left:10em;">Healthy volunteers: 2.5 mg/kg CBA IV every 12 hours, steady state: 1.79 ± 0.37 mg/L (Fan 2022).</p>
<p style="text-indent:-2em;margin-left:10em;">Patients who are critically ill: 0.875 to 1.58 mg/kg CBA IV every 8 or 12 hours, steady state: 2.93 mg/L (Markou 2008).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>AUC</b>
<b>
<sub></sub></b>
<b>(total):</b></p>
<p style="text-indent:-2em;margin-left:8em;">AUC<sub>0-24</sub>: Neonates (GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: 5 mg CBA/kg, single dose: 21.1 ± 8.1 mg•hour/L (Nakwan 2016).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults:</p>
<p style="text-indent:-2em;margin-left:10em;">AUC<sub>0-12</sub>: Healthy volunteers: 2.5 mg/kg CBA IV every 12 hours, steady state: 15.28 ± 3.29 mg•hour/L (Fan 2022).</p>
<p style="text-indent:-2em;margin-left:10em;">AUC<sub>0-24</sub>: Patients who are critically ill: 0.875 to 1.58 mg/kg CBA IV every 8 or 12 hours, steady state: 12.8 mg•hour/L (range: 6 to 20 mg•hour/L) (Markou 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Bacterial killing may continue after colistin concentration falls below the MIC of targeted pathogen and varies based on the organism, antimicrobial concentration, and duration of antimicrobial exposure:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>A. baumannii: </i>0 to &gt;7 hours (Rasidin 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>P. aeruginosa: </i>~1 to 1.5 hours (Bozkurt-Güzel 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with toxicity:</i> A C<sub>min </sub>&gt; ~2 to 2.4 mg/L has been associated with increased risk of nephrotoxicity (ESCMID/EUCAST [Tsuji 2019]; Forrest 2017; Horcajada 2016; Sorlí 2013).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038587"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alfacolin | Alficetin | Colistina richet | Colistina surar pharma | Cotrelan | Espirotech | Klonistina | Nolisim | Toliscrin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Colistin | Colistin astro | Tadim</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Gigabac | Megabac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Colistineb</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Colistin | Colistin tzf</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Colis tek | Colistimetato de sodio | Promixin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Colistin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Colimycin | Ke li si an</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Coliject | Colintensin | Colis tek | Colistimetato de sodio | Colomycin | Nolisim | Olixato</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Colistin | Colomycin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Colist | Colistiflex | Colistimethat natrium hikma | Colistin | Promixin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alfacolin | Colistina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Colistin | Colixin | Colomycin | Elistin | Sodium colistimethate g.e.s</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Colixin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Colimicina | Colistimetato de sodio accord | Colistimetato de Sodio Ges | Colistimetato de sodio xellia | Colixin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Colimycin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Colimycine | Colistimethate sodique medac | Colistimethate sodique panpharma</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Colomycin | Promixin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Colistin | Colistin/norma</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Colomycin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Kolistin Alvogen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Colistimethat natrium hikma | Colistin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Colomycin | Promixin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Coliracin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Colibug | Colicraft | Colifect | Coligetz | Colimista | Colina | Colinem | Colirem | Colist | Colisvio | Coly monas | Critimycin | Elistin | Ibicolist | Kabimethate | Kallistro | Kolax | Koolmete | Kuzet | Myxitin | Neolistim | Promistin | Remergin | Resilistin | Sava cms | Tough | Wockstin | Xylistin | Xylistin n | Zizant | Zolineg | Zycolis</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Colimicina | Colistimetato accord | Colistimetato Hikma | Colistimetato xellia | Pseudoneb</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Colistin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aldreb | Colimycin kaken | Colimycin kayaku</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Colimycin | Colis | Fucolistimetate | X colistin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Colistin JPI</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Colomycin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Colimycine | Colistin tzf</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Colimycine | Colistin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Colimycine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Colmesdant | Darogen</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Colistimethate | Colomycin | Xelcol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Colistimethaatnatrium eureco-pharma | Kolneb | Tadim</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Colimycin | Colomycin | Promixin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Colismet | Colistina | Colistipharm | Coltirox</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Colisan 2</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Coliate | Colicraft | Colimate | Colistat | Colistim | Nogotex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Colimycine | Colistin | Colomycin | Promixin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Colistimethate | Coly-mycin m</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Colimicina | Colistimetato accord | Colistimetato Hikma | Colistin Generis | Colixin | Colomycin ip</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Colistina bioethic | Colistina catedral | Colistina dasanti | Colistina dima | Colistina dutriec | Colistina gautier | Colistina richet | Etibac | Nolisim</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Colistina</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Colistimetat</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Colistin JPI</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tadim</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Colistin | Colistina generis | Colomycin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Colistate | Colistin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Colimycine | Colixin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Colimycin | Colitim | Kolisod | Kolistate | Kolistipol | Lixicol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Colimycin | Colistin | Costim | Locolin | Metacoli</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Colistin alvogen</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alfacolin | Avagal | Colistina Permatec | Colistina richet | Toliscrin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Colimycin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31487382">
<a name="31487382"></a>Abbott L, Plummer A, Hoo ZH, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD006682. doi:10.1002/14651858.CD006682.pub6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/31487382/pubmed" id="31487382" target="_blank">31487382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/Pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med.</i> 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31844014">
<a name="31844014"></a>Aguilera-Alonso D, Escosa-García L, Saavedra-Lozano J, Cercenado E, Baquero-Artigao F. Carbapenem-resistant gram-negative bacterial infections in children. <i>Antimicrob Agents Chemother</i>. 2020;64(3):e02183-19. doi:10.1128/AAC.02183-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/31844014/pubmed" id="31844014" target="_blank">31844014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30709064">
<a name="30709064"></a>Aitullina A, Krūmiņa A, Svirskis Š, Purviņa S. Colistin use in patients with extreme renal function: from dialysis to augmented clearance. <i>Medicina (Kaunas)</i>. 2019;55(2):33. doi:10.3390/medicina55020033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/30709064/pubmed" id="30709064" target="_blank">30709064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23840000">
<a name="23840000"></a>Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. <i>Clin Infect Dis</i>. 2013;57(9):1300-1303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23840000/pubmed" id="23840000" target="_blank">23840000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33108082">
<a name="33108082"></a>Aksoy GK, Özyazıcı-Özkan SE, Tezel G, Dayar GT, Köşker M, Doğan ÇS. Assessment of colistin related side effects in premature neonates. <i>Turk J Pediatr</i>. 2020;62(5):795-801. doi:10.24953/turkjped.2020.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/33108082/pubmed" id="33108082" target="_blank">33108082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24584997">
<a name="24584997"></a>Alan S, Yildiz D, Erdeve O, et al. Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by <i>Acinetobacter baumannii</i>. <i>Am J Perinatol</i>. 2014;31(12):1079-1086. doi:10.1055/s-0034-1371361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24584997/pubmed" id="24584997" target="_blank">24584997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34955517">
<a name="34955517"></a>Almangour TA, Alsubaie S, Ghonem L, Almohaini HA, Mohammed Bakheet H, Ikhlass A. Ceftazidime-avibactam for the treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> central nervous system infection in pediatric patient: a case report. <i>Pediatr Infect Dis J</i>. 2022;41(5):436-438. doi:10.1097/INF.0000000000003439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/34955517/pubmed" id="34955517" target="_blank">34955517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15705991">
<a name="15705991"></a>Alothman GA, Ho B, Alsaadi MM, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. <i>Chest</i>. 2005;127(2):522-529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/15705991/pubmed" id="15705991" target="_blank">15705991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28841583">
<a name="28841583"></a>Al Yazidi LS, McMullan B, Kohan S, Palasanthiran P. Persistent gram-negative neurosurgical meningitis in a neonate, successfully treated with intraventricular colistin: case report and review of the literature. <i>Pediatr Infect Dis J</i>. 2018;37(3):e79-e81. doi:10.1097/INF.0000000000001743<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28841583/pubmed" id="28841583" target="_blank">28841583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32198160">
<a name="32198160"></a>Ambreen G, Salat MS, Hussain K, et al. Efficacy of colistin in multidrug-resistant neonatal sepsis: experience from a tertiary care center in Karachi, Pakistan. <i>Arch Dis Child</i>. 2020;105(9):830-836. doi:10.1136/archdischild-2019-318067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/32198160/pubmed" id="32198160" target="_blank">32198160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics. Dicloxacillin. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33782000">
<a name="33782000"></a>Antachopoulos C, Geladari A, Landersdorfer CB, et al. Population pharmacokinetics and outcomes of critically ill pediatric patients treated with intravenous colistin at higher than recommended doses. <i>Antimicrob Agents Chemother</i>. 2021;65(6):e00002-21. doi:10.1128/AAC.00002-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/33782000/pubmed" id="33782000" target="_blank">33782000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28650936">
<a name="28650936"></a>Antachopoulos C, Iosifidis E. Colistin use in neonates and children with infections due to carbapenem-resistant bacteria. <i>Pediatr Infect Dis J</i>. 2017;36(9):905-907. doi:10.1097/INF.0000000000001655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28650936/pubmed" id="28650936" target="_blank">28650936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20585114">
<a name="20585114"></a>Antachopoulos C, Karvanen M, Iosifidis E, et al. Serum and cerebrospinal fluid levels of colistin in pediatric patients. <i>Antimicrob Agents Chemother</i>. 2010;54(9):3985-3987. doi:10.1128/AAC.01799-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20585114/pubmed" id="20585114" target="_blank">20585114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33713930">
<a name="33713930"></a>Atag E, Unal F, Arslan H, et al. The effect of nebulized antibiotics in children with tracheostomy. <i>Int J Pediatr Otorhinolaryngol</i>. 2021;143:110665. doi:10.1016/j.ijporl.2021.110665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/33713930/pubmed" id="33713930" target="_blank">33713930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33575996">
<a name="33575996"></a>Ayhan M, Kalem AK, Hasanoglu I, et al. Intrathecal and intraventricular administration of antibiotics in gram-negative nosocomial meningitis in a research hospital in Turkey. <i>Turk Neurosurg</i>. 2021;31(3):348-354. doi:10.5137/1019-5149.JTN.29844-20.2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/33575996/pubmed" id="33575996" target="_blank">33575996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour L, Flynn PM, Fekete T. Infections of cerebrospinal fluid shunts and other devices. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24728736">
<a name="24728736"></a>Bargiacchi O, Rossati A, Car P, et al. Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review. <i>Infection</i>. 2014;42(5):801-809. doi:10.1007/s15010-014-0618-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24728736/pubmed" id="24728736" target="_blank">24728736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barker.1">
<a name="Barker.1"></a>Barker AF. Bronchiectasis in adults: maintaining lung health. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9311714">
<a name="9311714"></a>Bauldoff GS, Nunley DR, Manzetti JD, et al. Use of Aerosolized Colistin in Cystic Fibrosis Patients Awaiting Lung Transplantation. <i>Transplantation</i>. 1997;64(5):748-752.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/9311714/pubmed" id="9311714" target="_blank">9311714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15190037">
<a name="15190037"></a>Benifla M, Zucker G, Cohen A, Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. <i>J Antimicrob Chemother</i>. 2004;54(1):290-292. doi:10.1093/jac/dkh289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/15190037/pubmed" id="15190037" target="_blank">15190037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25630411">
<a name="25630411"></a>Bergen PJ, Bulman ZP, Saju S, et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. <i>Pharmacotherapy</i>. 2015;35(1):34-42. doi:10.1002/phar.1537<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/25630411/pubmed" id="25630411" target="_blank">25630411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11706322">
<a name="11706322"></a>Beringer P. The Clinical Use of Colistin in Patients With Cystic Fibrosis. <i>Curr Opin Pulm Med</i>. 2001;7(6):434-440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/11706322/pubmed" id="11706322" target="_blank">11706322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15658071">
<a name="15658071"></a>Berlana D, Llop JW, Fort E. Badia MB, Jódar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. <i>Am J Health-Syst Pharm</i>. 2005;62(1):39-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/15658071/pubmed" id="15658071" target="_blank">15658071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1763528">
<a name="1763528"></a>Bosso JA, Liptak CA, Seilheimer DK, et al. Toxicity of Colistin in Cystic Fibrosis Patients. <i>DICP</i>. 1991;25(11):1168-1170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/1763528/pubmed" id="1763528" target="_blank">1763528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22126897">
<a name="22126897"></a>Bozkurt-Güzel C, Gerçeker AA. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. <i>J Antibiot (Tokyo).</i> 2012;65(2):83-86. doi:10.1038/ja.2011.101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22126897/pubmed" id="22126897" target="_blank">22126897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28135233">
<a name="28135233"></a>Çağan E, Kıray Baş E, Asker HS. Use of colistin in a neonatal intensive care unit: A cohort study of 65 patients. <i>Med Sci Monit</i>. 2017;23:548-554. doi:10.12659/msm.898213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28135233/pubmed" id="28135233" target="_blank">28135233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19892577">
<a name="19892577"></a>Cascio A, Conti A, Sinardi L, et al. Post-neurosurgical multidrug-resistant <i>Acinetobacter baumannii</i> meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. <i>Int J Infect Dis</i>. 2010;14(7):e572-e579. doi:10.1016/j.ijid.2009.06.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19892577/pubmed" id="19892577" target="_blank">19892577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35349496">
<a name="35349496"></a>Castagnola E, Ricci E, Mariani M. Infections due to antibiotic-resistant gram-negative bacteria in pediatrics: possible management strategies. <i>Pediatr Infect Dis J</i>. 2022;41(7):e283-e285. doi:10.1097/INF.0000000000003528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/35349496/pubmed" id="35349496" target="_blank">35349496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26318190">
<a name="26318190"></a>Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. <i>J Antimicrob Chemother.</i> 2015;70(12):3291-3297. doi:10.1093/jac/dkv267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/26318190/pubmed" id="26318190" target="_blank">26318190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32773667">
<a name="32773667"></a>Chin MKY, Hsia Y, Goossens H, et al. Evidence of dose variability and dosing below the FDA and EMA recommendations for intravenous colistin (polymyxin E) use in children and neonates. <i>Pediatr Infect Dis J</i>. 2020;39(11):1032-1034. doi:10.1097/INF.0000000000002847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/32773667/pubmed" id="32773667" target="_blank">32773667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31872226">
<a name="31872226"></a>Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. <i>J Pediatric Infect Dis Soc</i>. 2020;9(1):56-66. doi:10.1093/jpids/piz085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/31872226/pubmed" id="31872226" target="_blank">31872226</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Coly-Mycin M (colistimethate sodium) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11098334">
<a name="11098334"></a>Conway SP, Etherington C, Munday J, Goldman MH, Strong JJ, Wootton M. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. <i>Ann Pharmacother</i>. 2000;34(11):1238-1242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/11098334/pubmed" id="11098334" target="_blank">11098334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9487348">
<a name="9487348"></a>Conway SP, Pond MN, Watson A, et al. Intravenous Colistin Sulphomethate in Acute Respiratory Exacerbations in Adult Patients With Cystic Fibrosis. <i>Thorax</i>. 1997;52(11):987-993.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/9487348/pubmed" id="9487348" target="_blank">9487348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21988234">
<a name="21988234"></a>Couet W, Grégoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. <i>Clin Microbiol Infect</i>. 2012;18(1):30-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/21988234/pubmed" id="21988234" target="_blank">21988234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21544080">
<a name="21544080"></a>Couet W, Grégoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. <i>Clin Pharmacol Ther</i>. 2011;89(6):875-879.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/21544080/pubmed" id="21544080" target="_blank">21544080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22423120">
<a name="22423120"></a>Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. <i>Clin Infect Dis</i>. 2012;54(12):1720-1726.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22423120/pubmed" id="22423120" target="_blank">22423120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19460268">
<a name="19460268"></a>Dalgic N, Ceylan Y, Sancar M, et al. Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin. <i>Ann Trop Paediatr</i>. 2009;29(2):141-147.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19460268/pubmed" id="19460268" target="_blank">19460268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26228051">
<a name="26228051"></a>De Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant <i>Acinetobacter baumannii</i> meningitis.<i> Eur J Neurol</i>. 2016;23(1):68-75. doi:10.1111/ene.12789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/26228051/pubmed" id="26228051" target="_blank">26228051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34013828">
<a name="34013828"></a>Deniz M, Tapısız A, Börcek AÖ, Tezer H. Intraventricular treatment of paediatric meningitis due to extensively drug-resistant Gram-negative bacteria: two case reports and review of the literature. <i>J Chemother</i>. 2021;33(7):509-516. doi:10.1080/1120009X.2021.1920249<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/34013828/pubmed" id="34013828" target="_blank">34013828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20660694">
<a name="20660694"></a>Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. <i>Antimicrob Agents Chemother</i>. 2010;54(10):4503-4505.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20660694/pubmed" id="20660694" target="_blank">20660694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11106223">
<a name="11106223"></a>Döring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. <i>Eur Respir J</i>. 2000;16(4):749-767. doi:10.1034/j.1399-3003.2000.16d30.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/11106223/pubmed" id="11106223" target="_blank">11106223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24274315">
<a name="24274315"></a>Doshi NM, Cook CH, Mount KL, et al. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. <i>BMC Anesthesiology</i>. 2013;13(1):45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24274315/pubmed" id="24274315" target="_blank">24274315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33539569">
<a name="33539569"></a>Downes KJ, Goldman JL. Too much of a good thing: defining antimicrobial therapeutic targets to minimize toxicity. <i>Clin Pharmacol Ther</i>. 2021;109(4):905-917. doi:10.1002/cpt.2190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/33539569/pubmed" id="33539569" target="_blank">33539569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMA.1">
<a name="EMA.1"></a>European Medicine Agency (EMA). European Medicines Agency completes review of polymyxin-based medicine. Published October 24, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMC.1">
<a name="EMC.1"></a>EMC Web site. Colomycin Injection. https://www.medicines.org.uk/emc/medicine/1590. Accessed December 19, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Intensive Care Med</i>. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17126534">
<a name="17126534"></a>Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. <i>Int J Antimicrob Agents</i>. 2007;29(1):9-25. doi: 10.1016/j.ijantimicag.2006.08.024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/17126534/pubmed" id="17126534" target="_blank">17126534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16723606">
<a name="16723606"></a>Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. <i>Antimicrob Agents Chemother</i>. 2006;50(6):2274-2275.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16723606/pubmed" id="16723606" target="_blank">16723606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20658485">
<a name="20658485"></a>Falagas ME, Sideri G, Korbila IP, Vouloumanou EK, Papadatos JH, Kafetzis DA. Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. <i>Pediatr Pulmonol.</i> 2010;45(11):1135-1140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20658485/pubmed" id="20658485" target="_blank">20658485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35740204">
<a name="35740204"></a>Fan Y, Li Y, Chen Y, et al. Pharmacokinetics and pharmacodynamics of colistin methanesulfonate in healthy Chinese subjects after multi-dose regimen. <i>Antibiotics (Basel).</i> 2022;11(6):798. doi:10.3390/antibiotics11060798<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/35740204/pubmed" id="35740204" target="_blank">35740204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10825065">
<a name="10825065"></a>Fernandez-Viladrich P, Corbella X, Corral L, Tubau F, Mateu A. Successful treatment of ventriculitis due to carbapenem-resistant <i>Acinetobacter baumannii</i> with intraventricular colistin sulfomethate sodium. <i>Clin Infect Dis</i>. 1999;28(4):916-917. doi:10.1086/517243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/10825065/pubmed" id="10825065" target="_blank">10825065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28893780">
<a name="28893780"></a>Forrest A, Garonzik SM, Thamlikitkul V, et al. Pharmacokinetic/Toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients. <i>Antimicrob Agents Chemother.</i> 2017;61(11):e01367-17. doi:10.1128/AAC.01367-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28893780/pubmed" id="28893780" target="_blank">28893780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26801512">
<a name="26801512"></a>Fotakopoulos G, Makris D, Chatzi M, et al. Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin. <i>Acta Neurochir (Wien)</i>. 2016;158(3):603-610; discussion 610. doi:10.1007/s00701-016-2702-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/26801512/pubmed" id="26801512" target="_blank">26801512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21555763">
<a name="21555763"></a>Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. <i>Antimicrob Agents Chemother</i>. 2011;55(7):3284-3294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/21555763/pubmed" id="21555763" target="_blank">21555763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34469706">
<a name="34469706"></a>Goss CH, Heltshe SL, West NE, et al; STOP2 Investigators. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. <i>Am J Respir Crit Care Med</i>. 2021;204(11):1295-1305. doi:10.1164/rccm.202102-0461OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/34469706/pubmed" id="34469706" target="_blank">34469706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28614995">
<a name="28614995"></a>Greenwood J, Schwarz C, Sommerwerck U, et al. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary <i>Pseudomonas aeruginosa</i> infection. <i>Ther Adv Respir Dis</i>. 2017;11(7):249-260. doi:10.1177/1753465817710596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28614995/pubmed" id="28614995" target="_blank">28614995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hasbun.1">
<a name="Hasbun.1"></a>Hasbun R. Treatment of bacterial meningitis caused by specific pathogens in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24625200">
<a name="24625200"></a>Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic <i>Pseudomonas aeruginosa</i> infection. <i>Am J Respir Crit Care Med</i>. 2014;189(8):975-982.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24625200/pubmed" id="24625200" target="_blank">24625200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23070159">
<a name="23070159"></a>Healan AM, Gray W, Fuchs EJ, Griffiss JM, Salata RA, Blumer J. Stability of colistimethate sodium in aqueous solution. <i>Antimicrob Agents Chemother</i>. 2012;56(12):6432-6433<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23070159/pubmed" id="23070159" target="_blank">23070159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34738022">
<a name="34738022"></a>Heil EL, Bork JT, Abbo LM, et al. Optimizing the management of uncomplicated gram-negative bloodstream infections: consensus guidance using a modified delphi process. <i>Open Forum Infect Dis</i>. 2021;8(10):ofab434. doi:10.1093/ofid/ofab434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/34738022/pubmed" id="34738022" target="_blank">34738022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29743769">
<a name="29743769"></a>Hiremath P, Rangappa P, Jacob I, Rao K. Cerebrospinal fluid lactate as a prognostic indicator in postneurosurgical bacterial meningitis and use of intrathecal colistin. <i>Indian J Crit Care Med</i>. 2018;22(4):297-299. doi:10.4103/ijccm.IJCCM_418_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/29743769/pubmed" id="29743769" target="_blank">29743769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12358344">
<a name="12358344"></a>Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. <i>Eur Respir J</i>. 2002;20(3):658-664. doi:10.1183/09031936.02.00248102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/12358344/pubmed" id="12358344" target="_blank">12358344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26113262">
<a name="26113262"></a>Honore PM, Jacobs R, Hendrickx I, De Waele E, De Regt J, Spapen HD.. Nebulized colistin for treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: we still need to straighten out the dose! <i>Crit Care</i>. 2015;19:265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/26113262/pubmed" id="26113262" target="_blank">26113262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28128096">
<a name="28128096"></a>Horcajada JP, Sorlí L, Luque S, et al. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate.<i> Int J Antimicrob Agents.</i> 2016;48(6):725-727. doi:10.1016/j.ijantimicag.2016.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28128096/pubmed" id="28128096" target="_blank">28128096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24501388">
<a name="24501388"></a>Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. <i>Clin Infect Dis</i>. 2014;58(10):1439-1448. doi:10.1093/cid/ciu069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24501388/pubmed" id="24501388" target="_blank">24501388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32892635">
<a name="32892635"></a>Hussain K, Salat MS, Ambreen G, et al. Intravenous vs intravenous plus aerosolized colistin for treatment of ventilator-associated pneumonia - a matched case-control study in neonates. <i>Expert Opin Drug Saf</i>. 2020;19(12):1641-1649. doi:10.1080/14740338.2020.1819980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/32892635/pubmed" id="32892635" target="_blank">32892635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33553063">
<a name="33553063"></a>Hussain K, Sohail Salat M, Ambreen G, Iqbal J. Neurodevelopment outcome of neonates treated with intraventricular colistin for ventriculitis caused by multiple drug-resistant pathogens-a case series. <i>Front Pediatr</i>. 2021;8:582375. doi:10.3389/fped.2020.582375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/33553063/pubmed" id="33553063" target="_blank">33553063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30073562">
<a name="30073562"></a>Ilhan O, Bor M, Ozdemir SA, Akbay S, Ozer EA. Efficacy and safety of intravenous colistin in very low birth weight preterm infants. <i>Paediatr Drugs</i>. 2018;20(5):475-481. doi:10.1007/s40272-018-0301-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/30073562/pubmed" id="30073562" target="_blank">30073562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22687507">
<a name="22687507"></a>Imberti R, Cusato M, Accetta G, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. <i>Antimicrob Agents Chemother</i>. 2012;56(8):4416-4421. doi:10.1128/AAC.00231-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22687507/pubmed" id="22687507" target="_blank">22687507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20119725">
<a name="20119725"></a>Iosifidis E, Antachopoulos C, Ioannidou M, et al. Colistin Administration to Pediatric and Neonatal Patients. <i>Eur J Pediatr</i>, 2010;169(7):867-874.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20119725/pubmed" id="20119725" target="_blank">20119725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28501490">
<a name="28501490"></a>İpek MS, Aktar F, Okur N, Celik M, Ozbek E. Colistin use in critically ill neonates: A case-control study. <i>Pediatr Neonatol</i>. 2017;58(6):490-496. doi:10.1016/j.pedneo.2016.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28501490/pubmed" id="28501490" target="_blank">28501490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3301785">
<a name="3301785"></a>Jensen T, Pederson SS, Garne S, et al. Colistin Inhalation Therapy in Cystic Fibrosis Patients With Chronic <i>Pseudomonas aeruginosa</i> Lung Infection. <i>J Antimicrob Chemother</i>. 1987;19(6):831-838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/3301785/pubmed" id="3301785" target="_blank">3301785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25698772">
<a name="25698772"></a>Jitmuang A, Nation RL, Koomanachai P, et al. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. <i>J Antimicrob Chemother</i>. 2015;70(6):1804-1811. doi:10.1093/jac/dkv031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/25698772/pubmed" id="25698772" target="_blank">25698772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanafani.1">
<a name="Kanafani.1"></a>Kanafani ZA. Acinetobacter infection: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32115388">
<a name="32115388"></a>Kapnadak SG, Dimango E, Hadjiliadis D, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. <i>J Cyst Fibros</i>. 2020;19(3):344-354. doi:10.1016/j.jcf.2020.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/32115388/pubmed" id="32115388" target="_blank">32115388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23689704">
<a name="23689704"></a>Kapoor K, Jajoo M, Dublish S, Dabas V, Gupta S, Manchanda V. Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients. <i>Pediatr Crit Care Med</i>. 2013;14(6):e268-e272. doi:10.1097/PCC.0b013e31828a740f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23689704/pubmed" id="23689704" target="_blank">23689704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23507414">
<a name="23507414"></a>Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculitis and meningitis: a literature review. <i>Int J Antimicrob Agents</i>. 2013;41(6):499-508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23507414/pubmed" id="23507414" target="_blank">23507414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27474468">
<a name="27474468"></a>Karaiskos I, Friberg LE, Galani L, et al. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. <i>Int J Antimicrob Agents</i>. 2016;48(3):337-341. doi:10.1016/j.ijantimicag.2016.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/27474468/pubmed" id="27474468" target="_blank">27474468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147733">
<a name="23147733"></a>Karvanen M, Plachouras D, Friberg LE, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. <i>Antimicrob Agents Chemother</i>. 2013;57(1):668-671. doi:10.1128/AAC.00985-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23147733/pubmed" id="23147733" target="_blank">23147733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25461655">
<a name="25461655"></a>Kassamali Z, Jain R, Danziger LH. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics. <i>Int J Infect Dis</i>. 2015;30:125-132. doi:10.1016/j.ijid.2014.10.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/25461655/pubmed" id="25461655" target="_blank">25461655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23728146">
<a name="23728146"></a>Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. Polymyxins: wisdom does not always come with age. <i>Clin Infect Dis</i>. 2013;57(6):877-883. doi:10.1093/cid/cit367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23728146/pubmed" id="23728146" target="_blank">23728146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16145177">
<a name="16145177"></a>Katragkou A, Roilides E. Successful Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Central Nervous System Infections With Colistin. <i>J Clin Microbiol</i>. 2005;43(9):4916-4917.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16145177/pubmed" id="16145177" target="_blank">16145177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5448745">
<a name="5448745"></a>Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. <i>Ann Intern Med</i>. 1970;72(6):857-868.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/5448745/pubmed" id="5448745" target="_blank">5448745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25278817">
<a name="25278817"></a>Koerner-Rettberg C, Ballman M. Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy. <i>Core Evid</i>. 2014;9:99-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/25278817/pubmed" id="25278817" target="_blank">25278817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24189256">
<a name="24189256"></a>Koomanachai P, Landersdorfer CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. <i>Antimicrob Agents Chemother</i>. 2014;58(1):440-446.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24189256/pubmed" id="24189256" target="_blank">24189256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25643276">
<a name="25643276"></a>Landersdorfer CB, Nation RL. Colistin: How should it be dosed for the critically ill? <i>Semin Respir Crit Care Med</i>. 2015;36:126-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/25643276/pubmed" id="25643276" target="_blank">25643276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19821321">
<a name="19821321"></a>Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis. <i>Cochrane Database Syst Rev</i>. 2009;(4):CD004197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19821321/pubmed" id="19821321" target="_blank">19821321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440853">
<a name="28440853"></a>Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. <i>Cochrane Database Syst Rev</i>. 2017;4(4):CD004197. doi:10.1002/14651858.CD004197.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28440853/pubmed" id="28440853" target="_blank">28440853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34806975">
<a name="34806975"></a>Langton Hewer SC, Smyth AR, Brown M, et al. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and <i>Pseudomonas aeruginosa</i> infection: the TORPEDO-CF RCT. <i>Health Technol Assess</i>. 2021;25(65):1-128. doi:10.3310/hta25650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/34806975/pubmed" id="34806975" target="_blank">34806975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20500046">
<a name="20500046"></a>Le J, Ashley ED, Neuhauser MM, et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i>. 2010;30(6):562-584. doi:10.1592/phco.30.6.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20500046/pubmed" id="20500046" target="_blank">20500046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9762785">
<a name="9762785"></a>Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw MJ. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. <i>Eur Respir J</i>. 1998;12(3):592-594.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/9762785/pubmed" id="9762785" target="_blank">9762785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20500046">
<a name="20500046"></a>Le J, Ashley ED, Neuhauser MM, et al. Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria. <i>Pharmacotherapy</i>. 2010;30(6):562-584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20500046/pubmed" id="20500046" target="_blank">20500046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14585859">
<a name="14585859"></a>Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. <i>J Antimicrob Chemother</i>. 2003;52(6):987-992.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/14585859/pubmed" id="14585859" target="_blank">14585859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16931410">
<a name="16931410"></a>Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. <i>Lancet Infect Dis</i>. 2006;6(9):589-601.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16931410/pubmed" id="16931410" target="_blank">16931410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16251342">
<a name="16251342"></a>Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration. <i>Antimicrob Agents Chemother</i>,.2005;49(11):4814-4815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16251342/pubmed" id="16251342" target="_blank">16251342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21114395">
<a name="21114395"></a>Lim LM, Ly N, Anderson D, et al. Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing. <i>Pharmacotherapy</i>. 2010;30(12):1279-1291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/21114395/pubmed" id="21114395" target="_blank">21114395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35678460">
<a name="35678460"></a>Lipp MA, Crass RL, Fitzgerald LJ, et al. Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycin. <i>J Antimicrob Chemother</i>. 2022;77(9):2516-2521. doi:10.1093/jac/dkac187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/35678460/pubmed" id="35678460" target="_blank">35678460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23132092">
<a name="23132092"></a>Lu Q, Luo R, Bodin L, et al. Efficacy of High-Dose Nebulized Colistin In Ventilator-Associated Pneumonia Caused By Multidrug-Resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>. <i>Anesthesiology</i>. 2012;117(6):1335-1347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23132092/pubmed" id="23132092" target="_blank">23132092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19704130">
<a name="19704130"></a>Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. <i>Antimicrob Agents Chemother</i>. 2009;53(11):4907‐4910. doi:10.1128/AAC.00345-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19704130/pubmed" id="19704130" target="_blank">19704130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18343250">
<a name="18343250"></a>Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. <i>Clin Ther</i>. 2008;30(1):143-151. doi:10.1016/j.clinthera.2008.01.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/18343250/pubmed" id="18343250" target="_blank">18343250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25459739">
<a name="25459739"></a>Maskin LP, Setten M, Rodriguez PO, et al. Inhaled colistimethate sodium in ventilator-associated tracheobronchitis due to multidrug-resistant Gram-negative bacteria. <i>Int J Antimicrob Agents</i>. 2015;45(2):199-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/25459739/pubmed" id="25459739" target="_blank">25459739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18046039">
<a name="18046039"></a>McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. <i>N Engl J Med</i>. 2007;357(22):2310-2311.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/18046039/pubmed" id="18046039" target="_blank">18046039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18060758">
<a name="18060758"></a>Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associate pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study [published online ahead of print December 3, 2007]. <i>Respir Med</i>. 2008;102(3):407-412.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/18060758/pubmed" id="18060758" target="_blank">18060758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23540878">
<a name="23540878"></a>Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689. doi:10.1164/rccm.201207-1160oe<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23540878/pubmed" id="23540878" target="_blank">23540878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moiraghi.1">
<a name="Moiraghi.1"></a>Moiraghi A, Moiraghi P. Colistin in Organic Fluids. In, Herold M, Gabriel Z, eds. <i>Antibiotics: Advances in Research, Production and Clinical Use; Proceedings of the Congress on Antibiotics Held in Prague, 15-19 June, 1964</i>. London, Butterworths, 1966;188-192.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31469781">
<a name="31469781"></a>Nakwan N, Chokephaibulkit K, Imberti R. The use of colistin for the treatment of multidrug-resistant gram-negative infections in neonates and infants: a review of the literature. <i>Pediatr Infect Dis J</i>. 2019;38(11):1107-1112. doi:10.1097/INF.0000000000002448<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/31469781/pubmed" id="31469781" target="_blank">31469781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26065861">
<a name="26065861"></a>Nakwan N, Lertpichaluk P, Chokephaibulkit K, Villani P, Regazzi M, Imberti R. Pulmonary and systemic pharmacokinetics of colistin following a single dose of nebulized colistimethate in mechanically ventilated neonates. <i>Pediatr Infect Dis J</i>. 2015;34(9):961-963. doi:10.1097/INF.0000000000000775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/26065861/pubmed" id="26065861" target="_blank">26065861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27276179">
<a name="27276179"></a>Nakwan N, Usaha S, Chokephaibulkit K, Villani P, Regazzi M, Imberti R. Pharmacokinetics of colistin following a single dose of intravenous colistimethate sodium in critically ill neonates. <i>Pediatr Infect Dis J</i>. 2016;35(11):1211-1214. doi:10.1097/INF.0000000000001263<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/27276179/pubmed" id="27276179" target="_blank">27276179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20812247">
<a name="20812247"></a>Nakwan N, Wannaro J, Thongmak T, et al. Safety in Treatment of Ventilator-Associated Pneumonia Due to Extensive Drug-Resistant <i>Acinetobacter baumannii</i> With Aerosolized Colistin in Neonates: A Preliminary Report. <i>Pediatr Pulmonol</i>. 2011;46(1):60-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20812247/pubmed" id="20812247" target="_blank">20812247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26607424">
<a name="26607424"></a>Nation RL, Garonzik SM, Li J, et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? <i>Clin Infect Dis.</i> 2016;62(5):552-558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/26607424/pubmed" id="26607424" target="_blank">26607424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28011614">
<a name="28011614"></a>Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. <i>Clin Infect Dis</i>. 2017;64(5):565-571. doi:10.1093/cid/ciw839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28011614/pubmed" id="28011614" target="_blank">28011614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24107410">
<a name="24107410"></a>Nation RL, Li J, Cars O, et al. Consistent global approach on reporting of colistin doses to promote safe and effective use. <i>Clin Infect Dis.</i> 2014;58(1):139-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24107410/pubmed" id="24107410" target="_blank">24107410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16916866">
<a name="16916866"></a>Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. <i>J Antimicrob Chemother</i>. 2006;58(5):1078-1081.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16916866/pubmed" id="16916866" target="_blank">16916866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34588142">
<a name="34588142"></a>Nicholson TT, Smith A, McKone EF, Gallagher CG. Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: A systematic review. <i>J Cyst Fibros</i>. 2022;21(4):562-573. doi:10.1016/j.jcf.2021.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/34588142/pubmed" id="34588142" target="_blank">34588142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19733029">
<a name="19733029"></a>Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. <i>Diagn Microbiol Infect Dis</i>. 2009;65(4):431-434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19733029/pubmed" id="19733029" target="_blank">19733029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30722017">
<a name="30722017"></a>Ooi MH, Ngu SJ, Chor YK, Li J, Landersdorfer CB, Nation RL. Population pharmacokinetics of intravenous colistin in pediatric patients: implications for the selection of dosage regimens. <i>Clin Infect Dis</i>. 2019;69(11):1962-1968. doi:10.1093/cid/ciz067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/30722017/pubmed" id="30722017" target="_blank">30722017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20358244">
<a name="20358244"></a>Ozdemir H, Tapisiz A, Ciftçi E, et al. Successful treatment of three children with post-neurosurgical multidrug-resistant <i>Acinetobacter baumannii</i> meningitis. <i>Infection</i>. 2010;38(3):241-244.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20358244/pubmed" id="20358244" target="_blank">20358244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19433570">
<a name="19433570"></a>Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. <i>Antimicrob Agents Chemother</i>. 2009;53(8):3430-3436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19433570/pubmed" id="19433570" target="_blank">19433570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25939411">
<a name="25939411"></a>Polat M, Kara SS, Tapısız A, Tezer H, Kalkan G, Dolgun A. Treatment of ventilator-associated pneumonia using intravenous colistin alone or in combination with inhaled colistin in critically ill children. <i>Paediatr Drugs</i>. 2015;17(4):323-330. doi:10.1007/s40272-015-0133-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/25939411/pubmed" id="25939411" target="_blank">25939411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28889110">
<a name="28889110"></a>Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. <i>Eur Respir J</i>. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28889110/pubmed" id="28889110" target="_blank">28889110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31033908">
<a name="31033908"></a>Pratheep R, Ray S, Mukhopadhyay K, et al. First case report of intraventricular tigecycline in a neonate with extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculitis. <i>Pediatr Infect Dis J</i>. 2019;38(8):e172-e174. doi:10.1097/INF.0000000000002348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/31033908/pubmed" id="31033908" target="_blank">31033908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22762867">
<a name="22762867"></a>Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. Comparison of two treatment regimens for eradication of <i>Pseudomonas aeruginosa</i> infection in children with cystic fibrosis. <i>J Cyst Fibros</i>. 2013;12(1):29-34. doi:10.1016/j.jcf.2012.06.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22762867/pubmed" id="22762867" target="_blank">22762867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15811909">
<a name="15811909"></a>Quinn AL, Parada JP, Belmares J, et al. Intrathecal Colistin and Sterilization of Resistant <i>Pseudomonas aeruginosa</i> Shunt Infection. <i>Ann Pharmacother</i>. 2005;39(5):949-952.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/15811909/pubmed" id="15811909" target="_blank">15811909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24673698">
<a name="24673698"></a>Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. <i>Ann Am Thorac Soc</i>. 2014;11(3):425-434. doi:10.1513/AnnalsATS.201311-395FR<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24673698/pubmed" id="24673698" target="_blank">24673698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33612816">
<a name="33612816"></a>Rasidin RSM, Suhaili Z, Mohamed AFS, Hod R, Neela V, Amin-Nordin S. Time-kill and post-antibiotic effect of colistin at different static concentrations in in vitro Acinetobacter baumannii. <i>Trop Biomed.</i> 2020;37(2):471-481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/33612816/pubmed" id="33612816" target="_blank">33612816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20876621">
<a name="20876621"></a>Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. <i>J Antimicrob Chemother</i>. 2010;65(12):2645-2649. doi:10.1093/jac/dkq360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20876621/pubmed" id="20876621" target="_blank">20876621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11402633">
<a name="11402633"></a>Reed MD, Stern RC, O'Riordan MA, et al. The Pharmacokinetics of Colistin in Patients With Cystic Fibrosis. <i>J Clin Pharmacol</i>. 2001;41(6):645-654.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/11402633/pubmed" id="11402633" target="_blank">11402633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27576543">
<a name="27576543"></a>Riethmüller J, Herrmann G, Graepler-Mainka U, et al. Sequential inhalational tobramycin-colistin-combination in CF-patients with chronic <i>P. aeruginosa</i> colonization - an observational study. <i>Cell Physiol Biochem</i>. 2016;39(3):1141-1151. doi:10.1159/000447821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/27576543/pubmed" id="27576543" target="_blank">27576543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18281693">
<a name="18281693"></a>Rodríguez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. <i>J Antimicrob Chemother</i>. 2008;61(4):908-913. doi:10.1093/jac/dkn018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/18281693/pubmed" id="18281693" target="_blank">18281693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19436571">
<a name="19436571"></a>Sabuda DM, Laupland K, Pitout J, et al. Utilization of Colistin for Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i>. <i>Can J Infect Dis Med Microbiol</i>. 2008;19(6):413-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19436571/pubmed" id="19436571" target="_blank">19436571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29361414">
<a name="29361414"></a>Sahbudak Bal Z, Kamit Can F, Yazici P, et al. The evaluation of safety and efficacy of colistin use in pediatric intensive care unit: Results from two reference hospitals and review of literature. <i>J Infect Chemother</i>. 2018;24(5):370-375. doi:10.1016/j.jiac.2017.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/29361414/pubmed" id="29361414" target="_blank">29361414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34497678">
<a name="34497678"></a>Sari ND, Baltali S, Serin I, Antar V. Evaluation of intraventricular/intrathecal antimicrobial therapy in the treatment of nosocomial meningitis caused by multidrug-resistant gram-negative bacteria after central nervous system surgery. <i>Can J Infect Dis Med Microbiol</i>. 2021;2021:9923015. doi:10.1155/2021/9923015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/34497678/pubmed" id="34497678" target="_blank">34497678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26456474">
<a name="26456474"></a>Shofty B, Neuberger A, Naffaa ME, et al. Intrathecal or intraventricular therapy for post-neurosurgical Gram-negative meningitis: matched cohort study. <i>Clin Microbiol Infect</i>. 2016;22(1):66-70. doi:10.1016/j.cmi.2015.09.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/26456474/pubmed" id="26456474" target="_blank">26456474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simon.1">
<a name="Simon.1"></a>Simon RH. Cystic fibrosis: antibiotic therapy for pulmonary exacerbations. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 5, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simon.2">
<a name="Simon.2"></a>Simon RH. Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23957376">
<a name="23957376"></a>Sorlí L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. <i>BMC Infect Dis.</i> 2013;13:380. doi:10.1186/1471-2334-13-380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23957376/pubmed" id="23957376" target="_blank">23957376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17547727">
<a name="17547727"></a>Steinfort DP, Steinfort C. Effect of Long-Term Nebulized Colistin on Lung Function and Quality of Life in Patients With Chronic Bronchial Sepsis. <i>Intern Med J</i>. 2007;37(7):495-498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/17547727/pubmed" id="17547727" target="_blank">17547727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22379071">
<a name="22379071"></a>Taccetti G, Bianchini E, Cariani L, et al. Early antibiotic treatment for <i>Pseudomonas aeruginosa</i> eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. <i>Thorax</i>. 2012;67(10):853-859. doi:10.1136/thoraxjnl-2011-200832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22379071/pubmed" id="22379071" target="_blank">22379071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant <i>Acinetobacter baumannii</i>, and <i>Stenotrophomonas maltophilia</i> infections. <i>Clin Infect Dis</i>. 2022a;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35439291">
<a name="35439291"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). <i>Clin Infect Dis</i>. 2022b;75(2):187-212. doi:10.1093/cid/ciac268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/35439291/pubmed" id="35439291" target="_blank">35439291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22935871">
<a name="22935871"></a>Tamma PD, Newland JG, Pannaraj PS, et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. <i>Pediatr Infect Dis J</i>. 2013;32(1):17-22. doi:10.1097/INF.0b013e3182703790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22935871/pubmed" id="22935871" target="_blank">22935871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30576264">
<a name="30576264"></a>Thomas R, Velaphi S, Ellis S, et al. The use of polymyxins to treat carbapenem resistant infections in neonates and children. <i>Expert Opin Pharmacother</i>. 2019;20(4):415-422. doi:10.1080/14656566.2018.1559817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/30576264/pubmed" id="30576264" target="_blank">30576264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20729233">
<a name="20729233"></a>Tramper-Stranders GA, Wolfs TF, van Haren Noman S, et al. Controlled Trial of Cycled Antibiotic Prophylaxis to Prevent Initial <i>Pseudomonas aeruginosa</i> Infection in Children With Cystic Fibrosis. <i>Thorax</i>. 2010;65(10):915-920.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20729233/pubmed" id="20729233" target="_blank">20729233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy. <i>Clin Infect Dis</i>. 2005, 41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710469">
<a name="30710469"></a>Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i>. 2019;39(1):10-39. doi:10.1002/phar.2209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/30710469/pubmed" id="30710469" target="_blank">30710469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23989805">
<a name="23989805"></a>Tumbarello M, De Pacale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. <i>Chest</i>. 2013;144(6):1768-1775.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23989805/pubmed" id="23989805" target="_blank">23989805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice Guidelines for the Management of Bacterial Meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-UKCF.1">
<a name="UKCF.1"></a>UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis: 3rd edition. 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Information for Healthcare Professionals: Colistimethate (marketed as Coly-Mycin M and generic products). FDA Alert June 28, 2007. <a href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm</a>. Updated August 14, 2013. Accessed January 31, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25493971">
<a name="25493971"></a>Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. <i>Crit Care Med</i>. 2015;43(3):527-533.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/25493971/pubmed" id="25493971" target="_blank">25493971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27139161">
<a name="27139161"></a>VanDevanter DR, Flume PA, Morris N, Konstan MW. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. <i>J Cyst Fibros</i>. 2016;15(6):783-790. doi:10.1016/j.jcf.2016.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/27139161/pubmed" id="27139161" target="_blank">27139161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32179149">
<a name="32179149"></a>Wacharachaisurapol N, Phasomsap C, Sukkummee W, et al. Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients. <i>Int J Antimicrob Agents</i>. 2020;55(6):105940. doi:10.1016/j.ijantimicag.2020.105940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/32179149/pubmed" id="32179149" target="_blank">32179149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18606838">
<a name="18606838"></a>Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients [published online ahead of print July 7, 2008]. <i>Antimicrob Agents Chemother</i>. 2008;52(9):3047-3051.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/18606838/pubmed" id="18606838" target="_blank">18606838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23201321">
<a name="23201321"></a>Wang JH, Lin PC, Chou CH, et al. Intraventricular antimicrobial therapy in postneurosurgical Gram-negative bacillary meningitis or ventriculitis: a hospital-based retrospective study. <i>J Microbiol Immunol Infect</i>. 2014;47(3):204-210. doi:10.1016/j.jmii.2012.08.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23201321/pubmed" id="23201321" target="_blank">23201321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Waters.1">
<a name="Waters.1"></a>Waters I, Wilcox P, Chilvers M, et al. Cystic fibrosis: care guidelines specific to new acquisition of pulmonary bacteria. <a href="https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/cystic-fibrosis/care_guidelines_specific_to_new_acquisition_of_pulmonary_bacteria.pdf" target="_blank">https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/cystic-fibrosis/care_guidelines_specific_to_new_acquisition_of_pulmonary_bacteria.pdf</a>. Published February 2018. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22576791">
<a name="22576791"></a>Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. <i>Pharmacotherapy</i>. 2012;32(7):604-612. doi:10.1002/j.1875-9114.2012.01098.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22576791/pubmed" id="22576791" target="_blank">22576791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17214907">
<a name="17214907"></a>Yagmur R, Esen F. Intrathecal colistin for treatment of <i>Pseudomonas aeruginosa</i> ventriculitis: report of a case with successful outcome. <i>Crit Care</i>. 2006;10(6):428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/17214907/pubmed" id="17214907" target="_blank">17214907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. <i>Clin Infect Dis</i>. 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24550334">
<a name="24550334"></a>Yapa SWS, Li J, Patel K, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. <i>Antimicrob Agents Chemother</i>. 2014;58(5):2570-2579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24550334/pubmed" id="24550334" target="_blank">24550334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22949160">
<a name="22949160"></a>Young D, Zobell J, Waters C, et al. Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: IV. Colistimethate Sodium. <i>Ped Pulmonol</i>. 2013;48(1):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22949160/pubmed" id="22949160" target="_blank">22949160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35023664">
<a name="35023664"></a>Yurttutan S, Atalay BC. Short and long term side effect of colistin treatment in preterm infants. <i>Turk J Pediatr</i>. 2021;63(6):1108-1109. doi:10.24953/turkjped.2021.06.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/35023664/pubmed" id="35023664" target="_blank">35023664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23335739">
<a name="23335739"></a>Ziaka M, Markantonis SL, Fousteri M, et al. Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. <i>Antimicrob Agents Chemother</i>. 2013;57(4):1938-1940. doi:10.1128/AAC.01461-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23335739/pubmed" id="23335739" target="_blank">23335739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8879797">
<a name="8879797"></a>Zylberberg H, Vargaftig J, Barbieux C, et al. Prolonged Efficiency of Secondary Prophylaxis With Colistin Aerosols for Respiratory Infection Due to <i>Pseudomonas aeruginosa</i> in Patients Infected With Human Immunodeficiency Virus. <i>Clin Infect Dis</i>. 1996;23(3):641-643.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/8879797/pubmed" id="8879797" target="_blank">8879797</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13161 Version 259.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
